Fentomycin-1
Fentomycin-1 is a ferroptosis inducer. Fentomycin-1 activates lysosomal iron2+ under acidic conditions with hydrogen peroxide to form a reactive iron-oxo species, which induces oxidative degradation, oxidation, and lipolysis of membrane phospholipids, triggering ferroptosis. Fentomycin-1 can be used for the research of pancreatic ductal adenocarcinoma, breast cancer metastasis, and melanoma.
For research use only. We do not sell to patients.
- CAS No.: 3095435-04-1
- Formula: C56H66N8O6
- Molecular Weight:947.17
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Fentomycin-1 enhances iron-mediated oxidation of unsaturated phospholipids in a cell-free lysosome-like environment[1].
Fentomycin-1 (1 μM; 1 h) localizes to the plasma membrane under low endocytic flux conditions and accumulates in the endolysosomal compartment of HT-1080 cells at physiological temperature[1].
Fentomycin-1 (1-10 μM; 1-48 h) induces ferroptosis in HT-1080, primary PDAC, primary sarcoma, and 4T1 cells via membrane phospholipid oxidation[1].
Fentomycin-1 (Sublethal doses; 48 h) induces HT-1080 cells to acquire a ferroptosis-resistant, epithelial-like cell state characterized by upregulated ferroptosis suppressors, lysosome-associated proteins, and lipid metabolism pathways, alongside downregulated mesenchymal markers and iron homeostasis proteins[1].
Fentomycin-1 (5 μM; 72 h) eradicates Doxorubicin (HY-15142A)-induced drug-tolerant persister SUM159 triple-negative breast cancer cells in vitro[1].
Fentomycin-1 (1 μM; 24 h) reduces the CD44high subpopulation in primary human PDAC and UPS cells via ferroptosis[1].
Fentomycin-1 specifically activates lysosomal iron to induce ferroptosis and selectively targets iron-rich CD44high cancer cells[2].
Fentomycin-1 increases FSP1 mRNA levels in HT-1080 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HT-1080 fibrosarcoma cells
-
Concentration:1 μM
-
Incubation Time:1 h
-
Result:Localized to the plasma membrane under low endocytic flux conditions.
Accumulated in the endolysosomal compartment, colocalizing with LysoTracker, at 37°C.
Showed stronger endolysosomal accumulation than untethered Chen-White ligand, which had weak pan-cellular staining.
-
Cell Line:HT-1080 fibrosarcoma cells, human primary pancreatic ductal adenocarcinoma (PDAC) cells, human primary sarcoma cells, mouse 4T1 breast cancer cells
-
Concentration:1 μM; 2 μM; 10 μM
-
Incubation Time:1 h; 6 h; 24 h; 48 h
-
Result:Induced oxidation of membrane phospholipids in HT-1080 cells to a greater extent than well-established ferroptosis inducers.
Reduced phospholipid oxidation levels when co-treated with α-tocopherol, deferiprone, and liproxstatin-1.
Reduced cell viability, with cell death antagonized by ferroptosis inhibitors but not by apoptosis or necroptosis inhibitors.
Left residual toxicity despite ferroptosis inhibitor treatment.
Increased levels of lysophospholipids and glycerol, indicating oxidized phospholipid degradation.
-
Cell Line:Doxorubicin-induced drug-tolerant persister (DTP) SUM159 triple-negative breast cancer cells
-
Concentration:5 μM
-
Incubation Time:72 h
-
Result:Eradicated doxorubicin-induced DTP SUM159 cells, significantly reducing the number of colonies formed compared to vehicle treatment.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c (female, 6-8 weeks old, syngeneic 4T1 triple-negative breast cancer intranodal metastasis model)[1]
-
Dosage:0.003 mg per animal
-
Administration:intralymphatic; every other day
-
Result:Reduced intranodal tumour volume compared with vehicle control on day 10 post-treatment initiation.
Increased tumour-size-based survival, with a Mantel-Cox log-rank test P value of 8.7×10-5 compared with vehicle.
Reduced abundance of CD44high cancer cells from 20.2% in vehicle-treated mice to 11.0% in treated mice.
Increased oxidation of membrane phospholipids in residual tumours.
Caused no adverse effects on body weight.
Chemical Information
-
CAS No. 3095435-04-1
-
Molecular Weight 947.17
-
Formula C56H66N8O6
-
SMILES
O=C(C1=C(C2=C(C=C(C=C2)C)C=C1)C3=O)C4=C3C=CC5=C4N[C@@]6(C)C(OC(CCC(NCCCCNC7=CC=NC(CN8CCC[C@H]8[C@@H]9CCCN9CC%10=CC(N(C)C)=CC=N%10)=C7)=O)=O)[C@H](C)O[C@]5([H])C6
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
[1]. Cañeque T, et al. Activation of lysosomal iron triggers ferroptosis in cancer. Nature. 2025;642(8067):492-500. [Content Brief]
[2]. Ali Boubacar K, et al. Regulation of ferroptosis by BAP1. Cell Death Differ. 2026 Jan 23. [Content Brief]
[3]. Palma M, et al. Lymph node environment drives FSP1 targetability in metastasizing melanoma. Nature. 2026;649(8096):477-486. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Fentomycin-1
- 3095435-04-1
- Fentomycin1
- Fentomycin 1
- Ferroptosis
- Reactive Oxygen Species (ROS)
- UPS cells
- sarcoma
- pancreatic ductal adenocarcinoma
- HT-1080 cells
- SUM159 triple-negative breast cancer cells
- CD44high cancer cells
- lysosomal iron(II)
- murine breast cancer models
- ferroptosis
- 4T1 cells
- Inhibitor
- inhibitor
- inhibit